⚠️ ALL PRODUCTS ARE FOR RESEARCH PURPOSES ONLY ⚠️
⚠️ ALL PRODUCTS ARE FOR RESEARCH PURPOSES ONLY ⚠️
$99.99 / month – $849.99
Advanced TB-500 nasal spray for tissue repair and recovery research. Needle-free peptide delivery with optimal bioavailability. Research-grade quality.
TB-500 nasal spray is an intranasal supply form of TB-500, a synthetic peptide derived from the highly conserved C-terminal region of Thymosin Beta-4 (Tβ4), the 43-amino acid actin-sequestering protein expressed in virtually all mammalian nucleated cells. TB-500 itself corresponds to the amino acid fragment Tβ4(17–23), carrying the sequence Ac-LKKTETQ, and is distinguished from full-length Tβ4 by its focused activity at the actin-binding domain responsible for most Tβ4’s downstream natural effects in lab models. The cell-level formula is C26H44N8O9 with a cell-level weight of about 616.67 g/mol.
Unlike injectable peptide formats, tb500 nasal spray delivers the active compound across the highly vascular nasal mucosa, offering researchers a non-injectable use route for lab studies examining tissue repair signaling, angiogenesis pathways, and actin dynamics. The nasal epithelium provides direct access to the systemic circulation via the submucosal capillary network, bypassing gut breakdown and first-pass hepatic body function — two of the principal barriers limiting oral uptake of peptide compounds. PrymaLab TB-500 Nasal Spray is produced under strict quality control protocols, verified by independent HPLC and mass spectrometry test, and supplied exclusively for qualified lab research uses.
| Specification | Detail |
|---|---|
| Compound | TB-500 (Thymosin Beta-4 fragment, Tβ417–23) |
| Sequence | Ac-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) |
| Cell-level Formula | C26H44N8O9 |
| Cell-level Weight | 616.67 g/mol |
| Form | Intranasal spray solution |
| Purity | ≥98% (HPLC-verified, per batch) |
| Testing | HPLC, mass spectrometry, sterility, endotoxin |
| Storage | Refrigerate at 2–8°C; protect from light and heat |
| Shelf life | Stable for up to 4 weeks refrigerated in solution; freeze-dried form stable 24+ months at −20°C |
| Intended Use | Lab research only — not for human or veterinary treatment use |
TB-500 exerts its principal natural effects through the G-actin sequestration and cell migration pathways originally identified in full-length Thymosin Beta-4. The peptide’s conserved LKKTET motif — identified by Goldstein et al. (1992) as the minimum active sequence needed for actin binding — binds G-actin (globular, monomeric actin) with high affinity, preventing its spontaneous polymerization into F-actin (filamentous actin). Because G-actin/F-actin equilibrium is the central regulator of cytoskeletal dynamics, cell motility, and wound contraction, TB-500’s tuning of this balance has downstream results across multiple tissue repair and regrowth pathways studied in lab models.
The principal mechanism of TB-500 involves binding to the N-terminus of G-actin monomers through the LKKTET hexapeptide motif, forming a 1:1 non-covalent complex that sequesters G-actin from the polymerization-competent pool. This shifts the key actin level — the minimum free G-actin level needed for net F-actin assembly — upward, blocking stress fiber formation while simultaneously increasing the available pool of monomeric actin that supports lamellipodia and filopodia extension at the leading edge of migrating cells. The practical result in tissue repair models is enhanced directional cell migration toward wound sites, with studies in corneal and dermal models showing measurable increases in keratinocyte and fibroblast migration velocity.
Beyond actin control, lab studies have showed that TB-500 promotes angiogenesis — the formation of new blood vessels from existing vasculature — in ischemic and wound healing tissue models. Philp et al. (2004, Annals of the New York Academy of Sciences) showed that Tβ4 and its derived fragments greatly upregulate VEGF (vascular endothelial growth factor) expression in endothelial cells, promote endothelial tube formation in Matrigel assays, and reduce ischemic tissue loss in cardiac injury models. The LKKTET fragment TB-500 retains this pro-angiogenic activity, making it a subject of ongoing research into tissue revascularization and ischemia healing models.
Tβ4 and TB-500 have been studied for their modulatory effects on swelling cytokine signaling, very NF-κB pathway activity. Lab data from corneal wound models show reduced swelling cell infiltration and decreased pro-swelling cytokine expression (including TNF-α and IL-1β) following Tβ4 use. Huff et al. (2001) proposed that Tβ4’s anti-swelling mechanism involves direct downregulation of NF-κB activity, which governs transcription of a broad array of swelling genes. This dual profile — promoting repair while tuning swelling — distinguishes TB-500 from peptides that address only a single component of the tissue injury response.
A distinct area of TB-500 research examines its role in cardiac progenitor cell recruitment and remodeling following myocardial injury. Bock-Marquette et al. (2004, Nature) showed that Tβ4 starts ILK (integrin-linked kinase), promotes survival signaling in cardiac progenitor cells, and boosts cardiomyocyte migration and differentiation in post-infarction animal models. Importantly, that work identified the LKKTET sequence as enough for ILK start — directly implicating the TB-500 fragment in these cardiac remodeling effects. This study remains one of the most-cited pieces of lab evidence in the Tβ4 / TB-500 research literature.
The following research context is drawn from peer-reviewed lab and translational literature. All data reflects experimental research settings. PrymaLab TB-500 Nasal Spray is supplied exclusively for laboratory research and is not intended for human or veterinary treatment use.
TB-500 and full-length Tβ4 have been extensively studied in cutaneous wound healing models. Experimental work using full-thickness dermal wounds in rodents shows accelerated wound closure, increased keratinocyte migration, enhanced granulation tissue formation, and improved collagen deposition quality in Tβ4-treated animals versus controls. Malinda et al. (1999) documented greatly faster wound healing rates in db/db diabetic mice — an animal model of impaired wound healing — following Tβ4 treatment, suggesting relevance to research on healing deficits in body disease contexts. The nasal spray supply format of TB-500 is of specific interest in systemic wound healing research models where repeated injectable use creates confounding tissue effects at injection sites.
The cornea is among the most studied tissues for Tβ4 and TB-500 activity, in part because ocular surface wounds are easily quantified and because the corneal epithelium expresses very high levels of endogenous Tβ4. Sosne et al. published multiple studies (2001–2004) showing that Tβ4 eyedrops accelerate corneal epithelial wound closure, reduce swelling infiltration, and decrease apoptosis in corneal epithelial cells following chemical injury. These findings led to Phase I and II clinical trials of Tβ4 eyedrops (RGN-259) for dry eye and neurotrophic keratopathy, making the ocular surface one of the most clinically advanced use areas for the broader Tβ4/TB-500 compound class.
Tendon, ligament, and muscle repair models represent a major area of TB-500 lab research interest. Animal studies have examined Tβ4’s effects on tendon-derived fibroblast proliferation, collagen fiber alignment, and biomechanical properties of healing tendons. Lab cardiac work has been extrapolated by research groups to skeletal muscle injury models, examining whether TB-500’s ILK-start and satellite cell recruitment effects documented in cardiac tissue extend to skeletal muscle regrowth following contusion or transection injuries. This area of TB-500 research remains active, with the nasal spray use format relevant for longitudinal studies examining systemic peptide uptake.
Emerging lab research has examined Tβ4 and TB-500 in central nervous system injury and brain safety models. Morris et al. (2014, Journal of Neurological Sciences) showed that systemic Tβ4 use improved neurological function and promoted oligodendrocyte survival and remyelination in experimental autoimmune encephalomyelitis (EAE) models. More work in traumatic brain injury models has examined Tβ4’s capacity to promote neurogenesis, reduce lesion volume, and improve behavioral outcomes in rodents. The intranasal supply route for TB-500 is of specific research interest in neurological models because the olfactory transport pathway provides direct access to the cerebrospinal fluid and brain parenchyma without relying on systemic distribution and blood-brain barrier passage.
Researchers often assess bpc-157 tb-500 nasal spray forms that combine both peptides, given their mechanistically paired profiles. The following comparison covers the key distinctions between the two compounds as studied in lab literature.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Synthetic fragment of Thymosin Beta-4 (Tβ417–23) | Synthetic fragment of Body Protection Compound from gastric juice |
| Main Mechanism | G-actin sequestration, ILK start, cell migration promotion | NO-system tuning, growth factor upregulation, FAK/paxillin signaling |
| Cell-level Weight | ~616.67 g/mol | ~1,419.5 g/mol |
| Sequence Length | 7 amino acids (Ac-LKKTETQ) | 15 amino acids |
| Main Research Areas | Wound healing, angiogenesis, cardiac remodeling, brain safety | Gut repair, tendon healing, systemic cytoprotection |
| Anti-swelling | NF-κB pathway tuning | COX pathway tuning, mast cell effects |
| Angiogenic Activity | Strong VEGF upregulation, endothelial tube formation | Moderate, mainly via NO-pathway endothelial effects |
| Half-life (Estimated) | Longer (days in lab models); less frequent dosing studied | Shorter; more frequent dosing typical in research protocols |
| Often Combined? | Yes — often stacked with BPC-157 as paired repair peptides | Yes — often stacked with TB-500 |
The bpc 157 tb 500 nasal spray mix — colloquially referred to as the Wolverine nasal spray blend in the research community — is a common dual-peptide form studied for its possibly combined effects across multiple tissue repair pathways. TB-500 adds angiogenic, actin-control, and ILK-start signals while BPC-157 adds gut cytoprotective, tendon fibroblast, and systemic NO-pathway effects. PrymaLab offers this dual form for researchers studying whether combined use produces additive or combined effects not saw with either peptide alone.
| Factor | Nasal Spray | Injectable (Under-skin/IM) |
|---|---|---|
| Use Route | Intranasal — across nasal mucosa | Under-skin or intramuscular injection |
| GI Breakdown | Bypassed | Bypassed |
| First-pass Body function | Reduced vs. oral; partial vs. injectable | Fully bypassed |
| CNS Access Possible | Direct olfactory pathway possible | Needs blood-brain barrier passage |
| Research Use Case | Longitudinal systemic studies; CNS-targeted models | Precise dose titration; pharmacokinetic studies |
| Tissue Artifact Risk | None at injection site | Local tissue response possible at injection site |
PrymaLab formulates TB-500 Nasal Spray mainly for the standards demanded by serious lab research. Every batch begins with ≥98% pure TB-500 peptide (Ac-LKKTETQ) confirmed by reverse-phase HPLC and validated by mass spectrometry before any form step begins. The nasal spray vehicle is optimized for peptide shelf life and mucosal uptake, with pH and tonicity adjusted to minimize mucosal irritation in research models while keeping peptide integrity throughout the product’s refrigerated shelf life.
Each production lot is assigned a unique lot number and is accompanied by a Certificate of Test documenting purity, identity, level, sterility, and endotoxin levels. This batch-level traceability is a non-negotiable requirement for data integrity in any publishable lab study. PrymaLab’s independent third-party testing protocol — conducted by accredited analytical laboratories outside our production chain — ensures that the purity data on your COA reflects an unbiased analytical result, not an internal quality control pass.
The intranasal spray format removes the need for mixing, removes syringe and needle consumables from research workflows, and removes injection-site tissue artifacts that can complicate histological test in longitudinal studies. For researchers modeling systemic TB-500 uptake, repeated CNS-targeted peptide supply, or direct comparisons of intranasal versus injectable use routes, PrymaLab’s nasal spray format provides a precisely characterized, research-grade starting material.
TB-500 is a synthetic heptapeptide corresponding to the amino acid sequence Ac-LKKTETQ, derived from the actin-binding domain (residues 17–23) of Thymosin Beta-4 (Tβ4), a 43-amino acid protein. While full-length Tβ4 has cell-level weight of about 4,964 g/mol and more natural activities mediated by other sequence regions, TB-500 isolates the LKKTET actin-sequestering motif responsible for Tβ4’s core effects on cell migration, angiogenesis, and anti-swelling signaling in lab models. TB-500 is greatly smaller and easier to synthesize at high purity than full-length Tβ4.
The term “Wolverine nasal spray” refers colloquially to a dual-peptide intranasal form combining BPC-157 and TB-500 in a single supply vehicle. The name references the rapid tissue repair linked with the Marvel character and has become a widely used informal descriptor in the research peptide community. The mix is studied for possibly paired or combined tissue repair effects, as BPC-157 and TB-500 operate through distinct but overlapping cell-level pathways — very in the areas of angiogenesis, fibroblast start, and anti-swelling signaling.
Intranasal supply bypasses gut breakdown and reduces first-pass hepatic body function compared to oral use, allowing a higher proportion of the gave peptide dose to reach systemic circulation. Also, the olfactory transport pathway provides a possible direct route to the central nervous system via the cribriform plate — a pharmacokinetic feature of specific interest in neurological research models. The precise uptake of intranasal TB-500 relative to under-skin injection depends on form parameters including vehicle pH, tonicity, and permeation enhancer use, and should be characterized within each specific research protocol.
PrymaLab TB-500 Nasal Spray should be stored refrigerated at 2–8°C, protected from direct light, and kept away from heat sources. The formulated solution is stable for about 4 weeks under refrigerated conditions. Do not freeze the liquid form. For long-term archival storage of reference material, freeze-dried TB-500 peptide is stable for 24 months or more at −20°C when stored desiccated and protected from freeze-thaw cycles. Always consult the Certificate of Test for lot-specific shelf life data.
TB-500 and BPC-157 are often used together in lab research protocols examining combined or comparative tissue repair signaling. Their mechanisms are distinct — TB-500 acts mainly through G-actin sequestration and ILK start while BPC-157 tunes the NO system and FAK/paxillin signaling — making them mechanistically paired rather than redundant. PrymaLab offers both compounds individually as well as in a combined nasal spray form for researchers mainly studying dual-peptide use effects. As with any multi-compound research protocol, appropriate controls and dose-response study are essential for data interpretation.
Every batch of PrymaLab TB-500 Nasal Spray is subject to a multi-stage quality control process. The raw TB-500 peptide is confirmed at ≥98% purity by reverse-phase HPLC and identity-verified by mass spectrometry prior to form. The finished nasal spray product undergoes sterility testing and endotoxin testing (LAL assay) to confirm suitability for lab natural research. Each batch is assigned a unique lot number with a full Certificate of Test available for download. Testing is conducted by independent, accredited third-party analytical laboratories to ensure unbiased results and full traceability from synthesis to supply.
No. TB-500 Nasal Spray supplied by PrymaLab is strictly a research compound intended for qualified lab research uses only. It is not approved by the FDA or any control authority for human treatment use, human consumption, or veterinary treatment. Full-length Thymosin Beta-4 (as RGN-137, RGN-259, and related forms) is the subject of ongoing clinical trials in specific treatment signs, but TB-500 as sold by PrymaLab remains exclusively a research-grade material. Researchers are responsible for ensuring compliance with all applicable institutional, local, and federal regulations governing research peptide use.
Research reproducibility depends entirely on the consistency and traceability of your starting materials. PrymaLab’s quality assurance framework for TB-500 Nasal Spray is built around four non-negotiable pillars: independent testing, batch-level records, form transparency, and supply chain traceability.
Every production batch of TB-500 peptide is tested by an independent, ISO/IEC 17025-accredited analytical laboratory using reverse-phase HPLC with UV detection at 220 nm (the standard absorbance wavelength for peptide bond quantification) and confirmed by high-resolution mass spectrometry for cell-level identity check. Endotoxin testing uses the Limulus Amebocyte Lysate (LAL) kinetic turbidimetric method to confirmed levels below the threshold for research-grade natural compounds. The finished nasal spray form undergoes pH check, osmolality testing, and sterility confirmation before release.
Certificates of Test are batch-specific — not generic documents. Each COA references the unique lot number assigned to your product, reports actual measured values (not “passing” designations), and identifies the testing laboratory and methodology used. This level of records is needed for any research where compound identity and purity must be defensible in a manuscript submission, institutional review, or control filing. PrymaLab makes each batch COA available for download at the time of buy and keeps archived records for full lot traceability.
For Research Use Only. PrymaLab TB-500 Nasal Spray is intended exclusively for qualified lab research use by trained laboratory professionals in appropriate research settings. This product is not intended for human consumption, human treatment use, veterinary treatment, or any use outside of controlled research environments. TB-500 has not been approved by the FDA or any equivalent control authority for treatment use in humans or animals. PrymaLab makes no claims about treatment effect, and all research uses described on this page are drawn from published lab literature. Researchers are solely responsible for ensuring that their use of this material complies with all applicable institutional policies, local regulations, and federal laws governing research compounds.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.